Moving on to second-line therapies in pediatric MS: Immunosuppression with cyclophosphamide.
E A
EA
Yeh
B
B
Weinstock-Guttman
D000293:Adolescent; D000367:Age Factors; D002648:Child; D002986:Clinical Trials as Topic / Q000592:standards; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D004351:Drug Resistance / Q000502:physiology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D018570:Risk Assessment; D055502:Secondary Prevention; D017211:Treatment Failure
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide